Mirum’s EXPAND study tests maralixibat for treatment-resistant cholestatic pruritus
Mirum will reveal LIVMARLI EXPAND Phase 3 results on October 12, testing whether maralixibat can treat itching in additional rare liver diseases.
Pharma & Biotech
Pharma & Biotech
Why Mirum Pharmaceuticals and Incyte’s zilurgisertib data could reset expectations in FOP treatment
Read how Mirum and Incyte’s zilurgisertib Phase 2 data could reshape FOP treatment, FDA review risk and rare disease strategy.
Pharma & Biotech
Can volixibat and brelovitug expand Mirum Pharmaceuticals’ rare liver disease ambitions?
Mirum Pharmaceuticals’ EASL 2026 data deepen its rare liver disease strategy. Find out what changes for PSC, HDV and PFIC care.
Pharma & Biotech
Is volixibat the next major growth lever for Mirum Pharmaceuticals beyond LIVMARLI?
Mirum has commercial momentum. VISTAS will test whether volixibat can extend that rare liver disease story into PSC.
Pharma & Biotech
What Mirum’s Bluejay acquisition reveals about its long-term liver disease strategy
Mirum adds brelovitug in HDV through Bluejay deal. See how this could redefine rare liver disease leadership ahead of AZURE Phase 3 results in 2026.
Pharma & Biotech
MRM-3379 enters patient testing for Fragile X syndrome in Mirum’s BLOOM Phase 2 trial
MRM-3379 enters Phase 2 testing for Fragile X syndrome. Find out what this means for PDE4D inhibition, IDD drug design, and future trial direction.